Adjustment for competing risk in kin-cohort estimation
Related Experiment Video
Updated: Aug 30, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Nilanjan Chatterjee1, Patricia Hartge, Sholom Wacholder
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20852, USA. chattern@mail.nih.gov
Abstract:
Kin-cohort design can be used to study the effect of a genetic mutation on the risk of multiple events, using the same study. In this design, the outcome data consist of the event history of the relatives of a sample of genotyped subjects. Existing methods for kin-cohort estimation allow estimation of the risk of one event at a time with the assumption that the censoring events are unrelated to the genetic mutation under study. These methods, however, may produce biased estimates of risk when multiple events are related to the genetic mutation, and follow-up of some of the events may be censored by the onset of other events. Using a competing risk framework to address this problem, we show that cause-specific hazard functions for carriers and noncarriers are identifiable from kin-cohort data. For estimation, we propose an extension of a composite-likelihood approach we described previously. We illustrate the use of the proposed method for estimation of the risk of ovarian cancer from BRCA1/2 mutations in the absence of breast cancer, based on data from the Washington Ashkenazi Kin-Cohort Study. We also evaluate the performance of the proposed estimation method, based on simulated data that were generated following the setup of the Washington Ashkenazi Study.
Related Concept Videos
Relative Risk
Assumptions of Survival Analysis
Kaplan-Meier Approach
Comparing the Survival Analysis of Two or More Groups
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio
For example, in a clinical trial evaluating a...
